https://news.abbvie.com/news/press-releases/therapeutic-area/oncology/ 肿瘤学 版权2021 en - us AbbVie新狗万平台活动闻中心 https://news.abbvie.com/news/press-releases/clinical-trial-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsedrefractory-b-cell-non-hodgkins-lymphoma-b-nhl-published-in-lancet.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, <跨类= " xn-location " >哥本哈根,丹麦< / span >, 9月9日,2021 & # 160;从AbbVie (NYSE: ABBV)和A / S公司(纳斯达克:GMAB)今天宣布<我> < / i >《柳叶刀》发表的结果剂量升级阶段的一部分1/2 EPCORE& # 8482;NHL-1 first-in-human(富士康)剂量升级和群体扩张的临床试验安全性、疗效的初步评价试验药物epcoritamab (DuoBody& # 174; -CD3xCD20)患者的复发/难治性b细胞非霍奇金淋巴瘤(B-NHL)。完整的手稿可以在<我> < / i > <我>《柳叶刀》< / i >的<目标= "平等" href = " https://c212.net/c/link/?t=0& l = en& o = 3238081 - 1 -和h = 1091736685和3 u = https % % 2 f % 2 fwww.thelancet.com % 2 fjournals % 2 flancet % 2 farticle % 2 fpiis0140 - 6736 (21) 00889 - 8 % 2 ffulltext& =网站“rel =“nofollow”> < / >的网站。Epcoritamab正在联合开发公司和AbbVie。< / p > 12325年 星期四,09年9月2021 07:09:00 EST https://news.abbvie.com/news/press-releases/abbvie-and-calico-announce-second-extension-collaboration-focused-on-aging-and-age-related-diseases.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >和< span class = " xn-location”>南旧金山,加利福尼亚州。< / span >, < span class = " xn-chron " > 7月27日,2021年< / span > AbbVie从生命科学(NYSE: ABBV)和棉布今天宣布一个扩展的尖端合作发现,市场开发和引进新的治疗患者与年龄相关的疾病,包括神经退化和癌症。这是第二个扩展合作的最初成立于2014年只< / p > 12310年 星期二,2021年7月27日08:07:00 EST https://news.abbvie.com/news/press-releases/venetoclax-venclexta-granted-us-fda-breakthrough-therapy-designation-btd-in-higher-risk-myelodysplastic-syndrome-mds.htm < p > < span class = " xn-location”>北芝加哥,病了。, July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA^®) in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes (MDS) based on revised International Prognostic Scoring System (IPSS-R). A BTD is intended to expedite the development and review of medications to treat a serious medical condition and is granted when preliminary clinical evidence indicates the investigational therapy may demonstrate substantial improvement over existing therapies.¹ This marks the sixth BTD granted to venetoclax.

12306年 结婚,2021年7月21日01:07:00 EST https://news.abbvie.com/news/press - releases/abbvie -练习-正确- - - - - - -获取teneoone -和-铅-资产tnb - 383 b - -潜在的-治疗复发或难治性myeloma.htm——多个 < p > < span class = " xn-location”>北芝加哥,病了。< / span >和< span class = " xn-location”>纽瓦克。< / span >, < span class = " xn-chron " > 6月24日2021年< / span > AbbVie从(NYSE: ABBV)和Teneobio,公司今天宣布收购TeneoOne AbbVie行使其专属权利,Teneobio的附属,Inc .和tnb - 383 b, BCMA-targeting免疫治疗的潜在治疗复发或难治性多发性骨髓瘤(R / R毫米)。In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study.  

12297年 星期四,2021年6月24日08:06:00 EST https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 6月12日,2021年< / span > AbbVie从(NYSE: ABBV)今天宣布了新的第三阶段发光研究的数据比较的有效性和安全性的组合IMBRUVICA <一口> < < /一口> (ibrutinib)加上VENCLEXTA <一口> < < /一口> / VENCLYXTO <一口> < < /一口> (venetoclax) (I + V)和苯丁酸氮芥+ obinutuzumab (C + O)患者的一线治疗慢性淋巴细胞白血病(CLL)或小淋巴细胞性淋巴瘤(SLL)曾活动性疾病需要治疗/国际研讨会慢性淋巴细胞白血病(iwCLL)标准。研究满足了主要终点的优越的无进展生存(PFS),由一个独立的审查委员会评估(IRC)人力资源0.216 (95% CI, 0.131 - -0.357;p & lt;0.0001),表明减少疾病恶化或死亡的风险,我+ V C + O相比大约78%。我+ V是第一个口服,每日一次,chemotherapy-free,固定的时间临床实验的组合。研究结果将会在欧洲血液学协会(EHA) 2021虚拟国会(< a href = " https://c212.net/c/link/?t=0& l = en& o = 3193897 - 1 -和h = 1800115991和3 u = https % % 2 f % 2 flibrary.ehaweb.org % 2 feha % 2 f2021 % 2 feha2021-virtual-congress % 2 f330172 % 2 farnon.kater.fixed-duration.ibrutinib.and.venetoclax.28i2bv29.versus.chlorambucil.html % 3 ff % 253 d0 dlisting % % 252 abrowseby % 253 d8 % 252 asortby % 253 d1 % 252 asearch % 253 dglow&抽象= + % 23 LB1902”rel = =“平等”>“nofollow”目标抽象# LB1902 < / >)最新抽象会话期间6月12日下午从4:00-5:30。c。< / p > 12293年 坐,2021年6月12日07:06:00 EST https://news.abbvie.com/news/press-releases/new-data-shows-abbvies-venclyxtovenclexta-fixed-duration-combination-demonstrates-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-patients-after-three-years-off-treatment.htm < p > < span class = " xn-location”>北芝加哥,病了。< /跨度>、<跨类= " xn-chron " > 6月11日,2021年< / span >,从AbbVie (NYSE: ABBV)今天宣布的四年随访结果分析阶段3 CLL14试验,这表明,以前未经治疗的慢性淋巴细胞白血病(CLL)患者与治疗并发症VENCLYXTO <一口> < < /一口> / VENCLEXTA <一口> < < /一口> (venetoclax) + obinutuzumab继续显示再无进展生存(PFS)和较高的检测微小残留病(MRD)相比,病人接受标准治疗chemoimmunotherapy方案obinutuzumab和苯丁酸氮芥。今天第一次提供的数据在虚拟26 <一口> th < /一口>欧洲血液学协会(EHA)年度大会(抽象# S146)。< / p > 12292年 星期五,2021年6月11日01:06:00 EST https://news.abbvie.com/news/press-releases/captivate-study-shows-an-imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-chemotherapy-free-combination-has-potential-to-provide-remission-after-fixed-duration-treatment-for-chronic-lymphocytic-leukemia-cll.htm < p > < span class = " xn-location”>北芝加哥,病了。, June 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA^® (ibrutinib) in combination with VENCLEXTA^®/VENCLYXTO^® (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501). The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). The CR rate was consistent across all patients in the study including high-risk CLL patient groups. Furthermore, 24-month progression free survival (PFS) and overall survival (OS) were 95% and 98%, respectively. 

12289年 妈,07年6月2021 11:06:00 EST https://news.abbvie.com/news/press-releases/results-from-imbruvica-ibrutinib-resonate-2-study-provide-up-to-seven-years-progression-free-and-overall-survival-data-in-first-line-chronic-lymphocytic-leukemia-cll.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 6月4日2021 < / span >,从AbbVie (NYSE: ABBV),今天宣布延长长期的数据第三阶段RESONATE-2研究(< a href = " https://c212.net/c/link/?t=0& l = en& o = 3185673 - 1, h = 2921112925和3 u = https % % 2 f % 2 fclinicaltrials.gov % 2 fct2 % 2 fshow % 2 fnct01722487 % 3 fterm % 3 dpharmacyclics % 26电导率% 3 dchronic % 2 blymphocytic % 2 bleukemia % 26排名% 3 d7& = pcyc - 1115 % 2 f1116”rel = =“平等”>“nofollow”目标PCYC-1115/1116 < / >)评估单IMBRUVICA (ibrutinib)和苯丁酸氮芥和用7年的随访患者的慢性淋巴细胞白血病/小淋巴细胞性淋巴瘤(慢性淋巴细胞白血病/ SLL)。<一口> 1 < / >共舞,这些数据将在<跨类= " xn-chron " > 6月4日< / span > <一口> th < /一口>在2021年美国临床肿瘤学会学会年会(< a href = " https://c212.net/c/link/?t=0& l = en& o = 3185673 - 1 -和h = 1127020145和3 u = https % % 2 f % 2 fmeetinglibrary.asco.org % 2 frecord % 2 f198840 % 2 fabstract&抽象= + % 237523”rel = =“平等”>“nofollow”目标抽象# 7523 < / >)。此外,新数据将在欧洲血液学协会(EHA)虚拟国会从<跨类= " xn-chron " > 6月上行线< / span >,包括从informCLL&trade发现;真实前瞻性登记评估真实的治疗模式结合国家综合癌症网络(机构<一口> < < /一口>)推荐方案用于慢性淋巴细胞白血病/ SLL。< / p > 12288年 星期五,04年6月2021 09:06:00 EST https://news.abbvie.com/news/press-releases/abbvie-receives-european-commission-approval-venclyxto-venetoclax-in-combination-with-hypomethylating-agent-for-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 5月25日2021年< / span >,从AbbVie (NYSE: ABBV)今天宣布,欧盟委员会(EC) approved  VENCLYXTO <一口> < < /一口> (venetoclax)结合hypomethylating代理,阿扎胞苷或decitabine,新诊断的患者治疗成人急性髓系白血病(AML)是谁没有资格为密集化疗。<一口> 1 < /一口>,批准是有效的在所有27个成员国的欧盟,以及冰岛< span class = " xn-location " > < / span >, < span class = " xn-location " >列支敦士登< / span >,和<跨类= " xn-location " >挪威< / span >。< / p > 12281年 2021年5月25日星期二08:05:00 EST https://news.abbvie.com/news/press releases/abbvie -展示广度-肿瘤学投资组合-和-管线- - 2021 asco -和- eha年度congresses.htm < p > < span class = " xn-location”>北芝加哥,病了。, May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17).

12274年 2021年5月19日结婚08:05:00 EST https://news.abbvie.com/news/press-releases/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-combination-regimen-for-adult-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 4月23日2021年< / span > AbbVie从(NYSE: ABBV)今天宣布,对人用药品委员会(CHMP)的欧洲药品局(EMA) VENCLYXTO®采取了积极的意见;(venetoclax)结合hypomethylating代理新诊断患者治疗成人急性髓系白血病(AML)是谁没有资格为密集化疗。积极CHMP的观点是科学推荐营销授权欧盟委员会(EC),预计交付最终决定VENCLYXTO联合治疗用于AML在2021年上半年。< / p > 12266年 星期五,2021年4月23日08:04:00 EST https://news.abbvie.com/news/press-releases/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >和< span class = " xn-location”>伯克利,加州。< / span >,只2月10日,2021年,从AbbVie (NYSE: ABBV)和北美驯鹿生物科学,Inc .,主要临床分期CRISPR基因组编辑生物科技公司,今天宣布,他们已经进入了协作和许可协议的研究和开发嵌合抗原受体(车)- t细胞疗法。狗万正网地址虽然同种异体,“off-the-shelf"CAR-T细胞疗法显示早期承诺在一些癌症患者,需要克服排斥同种异体CAR-T细胞通过宿主的免疫系统更广泛的开发仍然是一个关键的挑战。狗万正网地址使用驯鹿# 39;s CRISPR基因组编辑平台工程师CAR-T细胞抵抗宿主免疫攻击将使下一代的发展“off-the-shelf"狗万正网地址细胞疗法更广泛的患者人群中获益。< / p > 12244年 结婚,在美国东部时间2021年2月10 08:02:00 https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-us-prescribing-information-updated-to-include-long-term-data-for-waldenstrms-macroglobulinemia-wm.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 12月。2020 < / span >,从AbbVie (NYSE: ABBV)今天宣布,美国食品和药物管理局(FDA)批准的更新IMBRUVICA <一口> < < /一口> (ibrutinib)处方信息包括疗效和安全性数据的组合与利妥昔单抗治疗Waldenströ IMBRUVICA;猴# 39;s巨球蛋白血(WM),基于第三阶段的最终分析创新研究。2013年首次批准,IMBRUVICA目前可用的几种类型的患者血液癌症,以及慢性移植物抗宿主病。2015年批准作为WM单药治疗和联合治疗与利妥昔单抗在2018年的基础上,主要分析创新。< / p > 12232年 结婚,2020年12月23日07:12:00 EST https://news.abbvie.com/news/press-releases/combined-data-from-multiple-phase-3-studies-imbruvica-ibrutinib-show-efficacy-and-safety-in-high-risk-previously-untreated-chronic-lymphocytic-leukemia-cll-and-real-world-data-indicating-low-biomarker-testing-rates-for-these-patients.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 12月。2020 < / span >,从AbbVie (NYSE: ABBV)今天宣布的结果两个三期临床研究的长期综合分析和额外的汇集分析评估的影响IMBRUVICA(基于ibrutinib)治疗高危患者的一线治疗慢性淋巴细胞白血病(CLL)。2020虚拟数据的整体特色美国血液学学会(灰)年会继续为CLL患者建立IMBRUVICA治疗的好处或没有高危疾病。< / p > 12224年 太阳,2020年12月06 13:12:00 EST https://news.abbvie.com/news/press-releases/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclextavenclyxto-venetoclax-in-chronic-lymphocytic-leukemia-cll.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 12月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布了新的,更新3慕拉诺岛和CLL14期临床试验的结果评估VENCLEXTA <一口> < < /一口> / VENCLYXTO <一口> < < /一口> (venetoclax)固定时间治疗组合虚拟62 <一口> nd < /一口>美国血液学学会年会(灰),博览会(摘要< a href = " https://c212.net/c/link/?t=0& l = en& o = 3003445 - 1, h = 1178697818和3 u = https % % 2 f % 2 fash.confex.com % 2烦恼% 2 f2020 % 2 fwebprogram % 2 fpaper136109.html& = 125”rel =“nofollow”目标= "平等" > 125 < / >,< a href = " https://c212.net/c/link/?t=0& l = en& o = 3003445 - 1, h = 4128814522和3 u = https % % 2 f % 2 fash.confex.com % 2烦恼% 2 f2020 % 2 fwebprogram % 2 fpaper136977.html& = 127”rel =“nofollow”目标= "平等" > 127 < / >,和< a href = " https://c212.net/c/link/?t=0& l = en& o = 3003445 - 1, h = 831638954和3 u = https % % 2 f % 2 fash.confex.com % 2烦恼% 2 f2020 % 2 fwebprogram % 2 fpaper134865.html& = 1310”rel =“nofollow”目标= "平等" > 1310 < / >,分别)。这些发现增加了越来越多的数据支持使用VENCLEXTA / VENCLYXTO之前在一线或慢性淋巴细胞白血病(CLL)患者治疗。< / p > 12223年 坐,2020年12月05 12:12:00 EST https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-high-rates-disease-free-survival-one-year-post-treatment-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 12月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布了新的数据阶段2 < a href = " https://c212.net/c/link/?t=0& l = en& o = 3003440 - 1 -和h = 2793823291和3 u = https % % 2 f % 2 fash.confex.com % 2烦恼% 2 f2020 % 2 fwebprogram % 2 fpaper134446.html& a =吸引“rel = =“平等”>“nofollow”目标吸引< / > (pcyc - 1142)临床试验评估IMBRUVICA <一口> < < /一口>,(ibrutinib)结合VENCLEXTA <一口> < < /一口> / VENCLYXTO <一口> < < /一口>,(venetoclax)以前未经治疗的患者慢性淋巴细胞白血病(CLL)或小淋巴细胞性淋巴瘤(SLL)在一次口头报告在2020虚拟会话美国血液学学会(灰)年度会议(文摘# 123)。一年期无病生存期(DFS)利率随机安慰剂的病人或ibrutinib在完成组合方案提供数据支持固定的时间治疗可以提供治疗慢性淋巴细胞白血病/ SLL患者缓解期和时间。< / p > 12222年 坐,2020年12月05 12:12:00 EST https://news.abbvie.com/news/press-releases/abbvie-and-frontier-medicines-establish-global-partnership-to-discover-and-develop-novel-therapies-and-e3-degraders-against-difficult-to-drug-targets.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >和< span class = " xn-location”>南旧金山,加利福尼亚州。< / span >, < span class = " xn-chron " > 12月。2020 < / span >,从AbbVie (NYSE: ABBV),全球生物制药公司研究,和前沿的药品,Corp .)、精密医学公司开发突破药物用药具有挑战性的目标蛋白质改变人类疾病的进程,今天宣布了一项全球战略合作发现,开发和商业化创新小分子疗法对管道的高利贷,difficult-to-drug蛋白质目标。< / p > 12220年 结婚,2020年12月02 08:12:00 EST https://news.abbvie.com/news/press releases/abbvie - -强调血液癌症-领导和推进-肿瘤学管道- -灰- 62年度meeting.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 11月。2020 < / span >,从AbbVie (NYSE: ABBV)宣布,它将从近40摘要血液癌症数据,包括10个口头报告,11个癌症在美国社会即将到来的虚拟血液学(灰)年度会议和博览会,<跨类= " xn-chron " > 12月5 - 8 < / span >。< / p > 12208年 星期四,2020年11月05 09:11:00 EST https://news.abbvie.com/news/press-releases/venclexta-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 10月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布,美国食品和药物管理局(FDA)提供了完整VENCLEXTA®批准;(venetoclax)结合with 阿扎胞苷或decitabine,或低剂量阿糖胞苷(LDAC)治疗最近确诊的急性髓系白血病(AML)的75岁或18岁以上的成年人或并发症,排除使用密集的诱导化疗。,批准支持的数据阶段3 VIALE-A  (m15 - 656) <我>,< / i >和VIALE-C (m16 - 043) <我>,< / i >研究和更新阶段的数据类< span = " xn-money " > 1 b < / span > m14 - 358和1/2 m14 - 387期研究。加快审批之前FDA授予VENCLEXTA这表明2018年。<一口> 5 < /一口> < / p > 12198年 星期五,2020年10月16日19:10:00 EST https://news.abbvie.com/news/press-releases/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncology-therapy.htm < p > < span class = " xn-location”>北芝加哥< / span >,,,, <跨类= " xn-location " >上海< / span >, <跨类= " xn-chron " > 9月。2020 < / span >,从AbbVie (NYSE: ABBV)和I-Mab(纳斯达克:IMAB)今天宣布,AbbVie I-Mab签署了一项广泛的、全球合作协议的开发和商业化lemzoparlimab(也称为TJC4),一个创新cd47抗体单克隆抗体在内部发现并由I-Mab治疗多种癌症。狗万正网地址此外,两个合作伙伴有可能扩大合作更多变革疗法只< / p > 12179年 星期五,2020年9月04 07:09:00 EST